Dermatophytic Onychomycosis Treatment Market Growth Rate Analysis 2026

Dermatophytic Onychomycosis Treatment Market – Size, Share, Outlook, and Opportunity Analysis 2018 - 2026
 
 
Spread the Word
Listed Under

Tag:
Dermatophytic Onychomycosis

Industry:
Health

Location:
Seattle - Washington - US

Subject:
Reports

SEATTLE - July 29, 2019 - PRLog -- Dermatophytic onychomycosis, also known as tinea unguium, is a fungal disease of toenails or fingernails that causes ring infection over nails. Trichophyton rubrum and trichophyton mentagrophytes are common strains of fungi responsible for causing dermatophytic onychomycosis. Furthermore, yeasts and non-dermatophyte molds are other agents that spread the infection. Public places such as gym, swimming pool, and others that are infected with disease causing fungal agents are major source, which cause dermatophytic onychomycosis. Moreover, continuous use of shoes for a longer duration and contact of toe nail with wet surface causes the fungal infection. Increasing incidences of the infection are evident in sportsperson, owing to continuous use of shoe, sweating at nails, and traumatic nail injuries.

Major symptoms of dermatophytic onychomycosis include thickening and whitening of nails. Moreover, the nails become brittle and appear white as the infection progresses. People suffering from diabetes, peripheral vascular disease, HIV, immune suppression, obesity, and geriatric population are at increased risk of this common fungal infection. Dermatophytic onychomycosis could be treated with either topical preparations or oral antifungal agents based on the severity of infection. The treatment often lasts for an average period of six months. In recent past, advancement in therapy with the introduction of effective topical and oral products has controlled the rapid spread of dermatophytic onychomycosis.

Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-sample/2053

The global dermatophytic onychomycosis treatment market size was valued at US$ 2,596.8 million in 2017, and is expected to witness a CAGR of 12.6% over the forecast period (2018 – 2026).

Dermatophytic onychomycosis is most common nail disorder. According to a report in the Journal of Cutaneous Medicine and Surgery, 2017, onychomycosis accounts for 50% of all nail diseases and prevalence of onychomycosis was estimated to be 5.5% with margin of error of + 3% worldwide. Prophylactic use of topical antifungal agent is expected to aid in effective treatment of dermatophytic onychomycosis, which in turn is major factor contributing to the market growth.

Key players operating in the dermatophytic onychomycosis treatment market include, Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy's Laboratories Ltd, Allergen, Inc., Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and Merz Pharma.

Detailed Segmentation:

Global Dermatophytic Onychomycosis Treatment Market, By Therapy Type:

• Systemic Therapy
• Topical Therapy
• Device-based Therapy

Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/dermatophytic-onychomycosis-treatment-market-2053

End
Email:***@coherentmarketinsights.com
Posted By:***@coherentmarketinsights.com Email Verified
Tags:Dermatophytic Onychomycosis
Industry:Health
Location:Seattle - Washington - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Coherent Market Insights PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share